Find recruiting clinical trials for breast cancer in the UK — including triple negative (TNBC), HER2+, HR+, and metastatic subtypes. See your treatment pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Treatment before or after surgery for early-stage disease
Standard: Chemotherapy, hormone therapy, HER2-targeted therapy, or combination
First treatment for advanced or metastatic breast cancer
Standard: Hormone therapy + CDK4/6 inhibitor (HR+) or Chemotherapy + HER2 therapy (HER2+)
After progression on 1st-line treatment
Standard: PI3K inhibitor, mTOR inhibitor, antibody-drug conjugate (Enhertu, Sacituzumab)
After multiple progressions — clinical trials are especially important
Standard: Clinical trial, further targeted therapy, or SAC
The most common subtype. Hormone receptor positive, HER2 negative. Treatments include hormone therapy, CDK4/6 inhibitors, and targeted therapies for specific mutations (ESR1, PIK3CA).
Overexpresses the HER2 protein. Treatments include trastuzumab, pertuzumab, T-DM1, and the newer antibody-drug conjugate Enhertu (trastuzumab deruxtecan).
Does not express estrogen, progesterone, or HER2 receptors. More aggressive but treatment is evolving rapidly with immunotherapy and antibody-drug conjugates like sacituzumab govitecan.
Loading trials from ClinicalTrials.gov...